Original Investigation

Psychopharmacology

, Volume 209, Issue 4, pp 303-311

Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation

  • Chad E. BeyerAffiliated withPfizer Global Research and Development CN8000Lohocla Research CorporationDepartment of Pharmacology, School of Medicine, University of Colorado Denver Email author 
  • , Jason M. DwyerAffiliated withPfizer Global Research and Development CN8000
  • , Brian J. PlattAffiliated withPfizer Global Research and Development CN8000
  • , Sarah NealAffiliated withPfizer Global Research and Development CN8000
  • , Bin LuoAffiliated withPfizer Global Research and Development CN8000
  • , Huai-Ping LingAffiliated withPfizer Global Research and Development CN8000
  • , Qian LinAffiliated withPfizer Global Research and Development CN8000
  • , Robert J. MarkAffiliated withPfizer Global Research and Development CN8000
  • , Sharon Rosenzweig-LipsonAffiliated withPfizer Global Research and Development CN8000
    • , Lee E. SchechterAffiliated withPfizer Global Research and Development CN8000

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Introduction

The effects of angiotensin (Ang) IV result from binding to a constitutively active metallopeptidase known as the AT4 receptor (or oxytocinase/insulin-regulated membrane aminopeptidase). While in vitro evidence indicates that Ang IV inhibits the peptidase activity of AT4 receptors, leading to increases in the concentrations of several peptides, including oxytocin, the consequence of inhibiting AT4 peptidase activity in vivo remains unresolved.

Discussion

Microdialysis coupled to immunoassay techniques revealed that systemic and intra-amygdala injection of Nle-Ang IV, a metabolically stable derivative of Ang IV, significantly elevated extracellular levels of oxytocin in the rat amygdala. Based on earlier reports describing the anxiolytic-like effects of oxytocin, we investigated whether disrupting AT4 peptidase activity would yield similar responses. In the mouse four-plate test, acute treatment with either Nle-Ang IV or LVV-hemorphin-7, a related AT4 receptor ligand, elicited significant increases in the number of punished crossings. These behavioral responses were comparable to the anxiolytic-like effects of oxytocin and to the standard anxiolytic agent, chlordiazepoxide. Cotreatment with either the AT4 receptor antagonist, divalinal, or the selective oxytocin receptor antagonist, WAY-162720, reversed the anxiolytic-like effects of Nle-Ang IV, while combining ineffective doses of Nle-Ang IV and oxytocin increased the number of punished crossings in this assay. Conversely, Nle-Ang IV and LVV-hemorphin-7 were inactive in the mouse tail suspension test of antidepressant activity. These findings represent the first in vivo demonstration of the peptidase activity of AT4 receptors, confirm the anxiolytic-like properties of Ang IV, and reveal a unique and previously uncharacterized relationship between AT4 and oxytocin receptor systems.

Keywords

AT4 receptors Nle-angiotensin IV LVV-hemorphin-7 Divalinal Oxytocin Anxiety